FIT - Project

Basic data

Title:

Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK- 3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group

Duration:

04/12/2015 to 03/12/2018

Abstract / short description:

Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK- 3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group

Keywords:

clinical trial

klinische Studie

Involved staff

Managers

Nikolaou, Konstantin

Faculty of Medicine
University of Tübingen

Cluster of Excellence: Image-Guided and Functionally Instructed Tumor Therapies (iFIT)
Centers or interfaculty scientific institutions

Contact persons

Ernemann, Ulrike

Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Diagnostic and Interventional Radiology